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INTRODUCTION
This update in the care of individuals with HIV reviews key
research publications from the past year relevant to General
Internal Medicine practitioners. Specific topics that we have
covered include new developments in the understanding of HIV
transmission, risk behavior among injection drug users, base-
line resistance testing, choice of initial treatment regimens, and
controversies in treatment interruption. Our selection process
was based on MEDLINE review of key journals by all authors
and recommendations of experts in this field. The original
MEDLINE review encompassed January 1, 2005 to March 1,
2006 and has been updated to Sepetember 1, 2006. Key
phrases used in the search included “HIV,” “AIDS,” “heterosex-
uality,” “antiretroviral treatment (ART)/highly active antiretro-
viral therapy (HAART),” “drug resistance,” and “risk behaviors”.
HIV TRANSMISSION
Epidemiologic studies suggest the risk of HIV infection per
heterosexual (coital) encounter (HIV infected to uninfected
partners) is approximately 1 in 1,000. However, this risk rate
seems low, given the spread of HIV during the past 20 to
30 years. As risk predictions are based on computer simula-
tions rather than observation in real populations, this popu-
lation-based study was undertaken to identify the risk of
contracting HIV during heterosexual coital sex.
In Rakai, Uganda, the researchers attempted to identify the
determinants of HIV transmission among monogamous, HIV
sero-discordant heterosexual couples.1 They retrospectively
identified 235 such couples where the HIV-uninfected partner
reported being monogamous. These data were analyzed from a
large, community-based randomized clinical trial previously
conducted from 1994 to 1999 involving 15,127 adult partici-
pants. The original study evaluated the efficacy of treating
sexually transmitted infections on the reduction of new HIV
infections. The researchers collected a large amount of behav-
ioral data and biological specimens from the participants
during in-home surveys conducted at 10-month intervals for
up to 40 months.
The median number of reported coital acts reported per
couple was 8.3 per month. There was no reported anal
intercourse, injection drug use (IDU), injected medication, or
transfusions. Only 29% of couples reported any condom use,
and none used condoms consistently. Overall, 68 of the 235
(29%) index partners transmitted HIV to their initially unin-
fected partner. The risk of transmission was higher among
those with very early HIV infection and those with late-stage
disease compared to those with chronic infection. In fact,
almost half (43%) of the index partners acquiring HIV during
the study transmitted the virus to their partner during the
acute HIV infection (the first 2.5 months after their serocon-
version). In addition, 37% of new infections were acquired from
index partners with late stage HIV disease (within 35–
61 months before death). The risk factors associated with
HIV transmission in an adjusted model were early/incident
HIV infection (aRR 4.98), late-stage HIV infection (aRR 3.49),
high HIV viral load (aRR 7.06), genital ulcer disease (aRR 2.03),
and younger age of the index partner (aRR 2.38). No significant
association was seen with the gender of the index partner,
circumcision status (of male index partners), AIDS-defining
symptoms, symptoms of discharge or dysuria, or laboratory
evidence of sexually transmitted infections (STIs).
This study presents the first observational data to confirm
the validity of earlier computer simulations that predicted the
greatest period of risk for viral transmission is during the
period of acute HIV infection. These results strongly suggest
that those with early HIV infection are a leading source of the
sexual spread of this infection. Although late-stage HIV disease
was also associated with an increased transmission risk,
individuals with more advanced disease reported fewer coital
acts, had fewer partners, and were more likely to have HIV
infected (not sero-discordant) partners.
This study has a number of limitations. It was performed in
rural Uganda and only evaluated monogamous, heterosexual
couples who did not report anal intercourse. Despite these
limits, the study findings have tremendous public health
implications and underscore the need to develop strategies to
identify people experiencing acute HIV infection so that we can
intervene to reduce their risk of transmitting the virus to
others.
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HIV TRANSMISSION AMONG INJECTION DRUG
USERS
Previous studies have demonstrated that HIV-positive injection
drug users (IDUs) in clinical care may harbor and transmit
drug-resistant HIV. Even those who are aware of their HIV
status may still share needles and/or injection equipment
(“works”). Few studies have examined the number of needle-
sharing events involving HIV drug-resistant strains and pro-
vided information about the number and perceived HIV
serostatus of sharing partners. Therefore, to characterize the
relationship between injection–drug risk behavior and drug
resistance and to estimate the likelihood of transmission of
resistant HIV, Kozal et al.2 performed a cross-sectional study of
HIV-positive IDUs in HIV care. The authors evaluated the
prevalence of drug-resistant HIV strains, the frequency with
which the patients shared needles and/or works, and the
number and perceived serostatus of needle-sharing partners
that were exposed to drug-resistant HIV. Patients were
recruited from a longitudinal study of HIV transmission risk
in patients engaged in HIV clinical care. One hundred eighty
HIV-positive patients with a history of IDU were enrolled in the
resistance substudy.
Fifty-five of the 180 subjects (31%) who used illicit drugs in
the last month were characterized as active drug users. During
that time, 22 (40% of active users) reported sharing needles/
works, 5 (23%) of whom had drug-resistant HIV. Only 8 of the
22 were on HIV antiretroviral medications. These 22 HIV-
positive active IDUs engaged in high-risk sharing practices 148
times with 296 partners, 271 (92%) of whom were believed to
be HIV-negative. Of the 296 partners, 44 (15%) were exposed to
high-risk IDU transmission behaviors by the 5 patients with
drug-resistant HIV during 27 sharing events.
These findings highlight that a significant proportion of
active IDUs in clinical care engage in high-risk IDU transmis-
sion behaviors. While a smaller proportion carry resistant HIV,
this small number can expose a substantial number of
partners because of multiple events related to sharing drugs/
works. Despite the fact that the majority of the HIV-positive
active IDUs in this sample recognized the risk to themselves
and others for HIV transmission via needle sharing, this
recognition appeared to be insufficient in deterring the
behavior.
HIV-positive IDUs who are receiving HIV care are available
for and should receive focused efforts to reduce IDU risk
behaviors, and subsequently, the transmission of sensitive and
resistant HIV.
PREVALENCE OF BASELINE RESISTANCE
Effective, sustained management of HIV infection with anti-
retroviral medications is limited by the fact that drug resis-
tance is common, and resistance to some drugs may confer
cross-resistance to other antiretrovirals, making regimen
selection a great challenge. Transmission of resistant HIV from
therapy-experienced individuals to others has been documen-
ted for a broad range of drug-resistant variants, so that clinical
concern about resistance exists for patients new to therapy
and for those who have been treatment-exposed. Patterns of
resistance could influence selection of initial treatment regi-
mens, postexposure prophylaxis regimens, and whether to
perform resistance testing in those seeking therapy for the first
time. The SPREAD Programme investigators studied HIV
patients from across Europe not previously exposed to anti-
retrovirals to determine the prevalence and patterns of trans-
mitted drug resistance.3
Patients from 19 European countries seen during 1996–
2002 were studied with genotype resistance assays. Of the
2,208 patients in the sample, about 1/3 (N=777) were recently
infected (less than 1 year), 607 had over a year of chronic
infection, and for the rest, the duration of infection was
unknown. By the International AIDS Society-USA mutation
definitions, about 10% of antiretroviral-naïve patients had at
least 1 resistance mutation. Resistance was more common in
recently infected patients (13.5%) than in those who had been
infected for more than a year (8.7%), or for an unknown
amount of time (8.7%; P=.006), suggesting that longer-
standing infections may have taken place at a time when
resistance was rarer, or alternatively that there may be
reversion to wild type in at least some patients over time. In
the 777 recently infected patients, nucleoside reverse-tran-
scriptase inhibitor-related resistance decreased from 13.4%
in early years (1996–1998) to 6.3% in later years (2001–2002),
likely owing to the improved effectiveness of antiretroviral
therapy over time. However, non-nucleoside reverse-transcrip-
tase inhibitor (NNRTI)-related resistance increased from 2.3% to
9.2% in later years when they were more commonly used.
Protease-inhibitor resistance was less than 5% and did not
change over time. When drug susceptibility interpretations were
done from genotypes using commonly available algorithms,
predicted high-level resistance was most common for drugs
with low genetic barriers to resistance development such as
NNRTIs and lamivudine.
Drug resistance was common in these European antire-
troviral-naïve patients, as it has been shown in studies in the
U.S. Overall, resistance rates may be increasing. This study
was large and geographically diverse, but still may not reflect
rates that would be seen elsewhere. Nevertheless, it suggests
that baseline genotyping may well be justified in many
clinical settings in patients with chronic or unknown dura-
tion of infection and those with acute infection. The risk of
transmission of resistant strains should be considered when
starting new regimens and in selecting empirically based
postexposure prophylaxis regimens. These and other data
have led to a change in Department of Health and Human
Services (DHHS) guidelines to recommend “performance of
genotypic resistance testing prior to initiation of antiretroviral
therapy in patients with acute or chronic HIV infection
(BIII).”4
SELECTION OF INITIAL ANTIRETROVIRAL REGIMEN
Treatment of HIV-infected, antiretroviral naïve patients con-
tinues to evolve, as new medications and fixed drug combina-
tions emerge.5 The DHHS guidelines recommend efavirenz or
lopinavir/ritanovir in combination with a backbone of 2
nucleoside reverse transcriptase inhibitors.4 In the efavirenz-
based regimen, the currently recommended nucleoside ana-
logs are zidovudine or tenofovir paired with lamivudine or
emtricitabine. With a lopanivir/ritonavir-based regimen, the
preferred nucleoside backbone is zidovudine plus either
lamivudine or emtricitabine. The recently released Interna-
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tional AIDS Society-USA Panel recommends the use of the
combination pills zidovudine/lamivudine, tenofovir/emtricita-
bine, or abacavir/lamivudine, used with either an NNRTI
(efavirenz or nevirapine) or a protease inhibitor (PI) (lopanivir,
atazanavir, fosamprenavir or saquinavir) boosted with ritona-
vir.6 Studies published this year are likely to impact future
DHHS recommendations.
Gallant and colleagues conducted a study to evaluate the
choice of nucleoside analog backbone. The open-label, ran-
domized study of 517 HIV infected, treatment-naïve patients,
compared tenofovir and emtricitabine once daily to the fixed-
dose zidovudine/epivir twice daily. Each nucleoside pairing
was given with once daily efavirenz. Subjects were primarily
white (60%) and male (86%). Approximately 50% of subjects in
each arm had baseline HIV polymerase chain reaction (PCR)
quantifications of greater than 100,000 copies/mL, and ap-
proximately 40% had CD4 counts <200 cells/mm3 at enroll-
ment. Although initially designed to test non-inferiority of
tenofovir to zidovudine, a 48-week data demonstrated that
significantly more patients in the tenofovir–emtricitabine
group reached the primary end point of HIV RNA quantifica-
tion of <400 copies/mL (84% vs 73%, P=.002) and <50 copies/
mL (80% vs 70%). In addition, patients receiving tenofovir–
emtricitabine had greater increases in CD4 cell count (190 vs
158 cells/mm3, P=.002) compared to zidovudine/lamivudine.
Some of the results can be explained by the higher drop out
rate for patients in the zidovudine/lamivudine arm (9%
discontinuation zidovudine–lamivudine vs 4% for tenofovir–
emtricitabine), primarily because of anemia. Interestingly, no
patients developed the K65R mutation, the expected mutation
for tenofovir failure. There was also a suggestion that there was
some limb lipoatrophy in patients receiving zidovudine while
limb fat measurements in patients receiving tenofovir were
essentially normal. Unfortunately, dual-energy x-ray absorp-
tiometry (DEXA) scans were only performed on 100 subjects,
and there were no baseline measurements. Final lipid data
were not included in this study.
These data are consistent with a previously published study
comparing tenofovir to stavudine, each combined with lami-
vudine and efavirenz.7 This prospective, randomized, double-
blind study of approximately 600 ART naïve subjects (25%
female, 64% white) demonstrated the non-inferiority of tenofo-
vir to stavudine. By week 144, the intention-to-treat analysis
demonstrated similar proportions of patients with HIV RNA
viral load of less than 400 copies/mL (76% vs 72%) and <50
copies/mL (73% vs 69%). Eight subjects did develop the K65R
mutation, suggesting that there may be a difference in
lamivudine versus emtricitabine (used in study 934, above).
Tenofovir subjects had better lipid and body fat outcomes,
while renal safety, a concern with this drug, was similar
between the two groups.
These data suggest that tenofovir–emtricitabine is likely to
become the preferred nucleoside starting regimen, especially
when used in combination with efaverinz. This is especially
important as a one pill, once a day combination of tenofovir,
emtricitabine, and efavirenz has just been approved by the FDA.
Although these data are very exciting for patients and
providers, there are some limitations to these studies. Because
of the teratogenicity of efavirenz, these studies excluded female
patients who were pregnant, and all enrolled patients were
required to use an effective contraceptive method throughout
the study. In addition, patients with preexisting renal insuffi-
ciency [glomerular filtration rate (GFR)<50 mL/min] and those
receiving nephrotoxic drugs were excluded because tenofovir is
associated with a greater decline in renal function than other
nucleosides and may cause acute renal failure.8 Finally,
patients enrolled in clinical trials are often more adherent to
medications than those in clinical practice. Lesser degrees of
adherence may lead to more resistance with efavirenz-based
regimes where the barrier to resistance is lower than protease
inhibitor-based regimens. In addition, the possibility of baseline
resistance to one or more of the drugs in the combination pill
needs to be considered (see above). Overall, one pill does not fit
all: therapy should still be tailored to the individual patient.
CONTROVERSIES IN CD4-GUIDED INTERMITTENT
THERAPY
Concerns over adverse effects of continuous antiretroviral
therapy such as development of resistance, side effects, long-
term toxicity, decreased quality of life, and cost have contrib-
uted to the consideration of CD4-guided treatment interrup-
tion. In this paradigm, once the CD4 count is above a
predetermined level, antiretroviral therapy is discontinued.
The CD4 count is then followed and therapy resumed once
the CD4 declines to a designated threshold value. In this
manner, the patient cycles on and off therapy. Previously,
small studies using CD4-guided therapy have shown that
patients can remain off therapy for an average of 8–12 months,
do not develop significant resistance, and although there is a
rapid increase in viral load to pretreatment levels after
stopping therapy, patients have a good response when therapy
is resumed. However, these trials were small and did not have
hard clinical outcomes.
This year, data from a larger study of CD4-guided therapy,
the Strategies for Management of Antiretroviral Therapy
(SMART) trial, were reported.9 In this trial, 5,472 patients from
a variety of international sites were randomized to either
continuous treatment with a goal of maintaining full viral
suppression or to the CD4-guided drug conservation arm with
a goal of limiting exposure to antiretroviral therapy. In the
latter arm, antiretroviral therapy was given intermittently
depending on the CD4 count: therapy was discontinued if the
CD4 count was above 350 cells/mm3 and resumed when the
CD4 count fell to below 250 cells/mm3.
The primary end points were defined as HIV progression or
death. The baseline characteristics in the two groups were well
matched for baseline and nadir CD4. Patients had a median
baseline CD4 of 600 cells/mm3 at enrollment, and the median
lifetime nadir was 250 cells/mm3. Overall, 25% of each group
had been AIDS defined, and 70% had viral suppression at
baseline. Very few patients were treatment naïve, and the
median time on antiretroviral therapy was 6 years.
The SMART study was stopped early because the CD4-
guided intermittent therapy arm had significantly higher
number of events (HIV progression and death) than the viral
suppression arm. The overall event rate in the drug conserva-
tion arm was 3.7 events per 100 patient years versus 1.5 in
the continuous treatment arm, a relative risk of 2.5 (P<.0001).
In addition, severe complications (myocardial infarction,
stroke, progression of liver and kidney disease) were also
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found to be increased in the treatment interruption group (RR
1.62). Subgroup analysis did not find any correlation with
CD4 nadir or baseline CD4 count: the relative risk of
discontinuing therapy was approximately equivalent for all
groups examined.
One potential explanation of the results may be because of
differences in CD4 counts during the trial. The CD4-guided
therapy group spent over 30% of the time at CD4 counts below
350 cell/mm3 and below 250 cell/mm3, greater than 10% of
the time compared to 9% and 2%, respectively, for the
continuous treatment arm. An alternative possibility is that
the results may be explained by the level of HIV viremia.
Although the viral load data have not been reported, in the
continuous therapy arm, patients were on therapy 93% of the
time, whereas in the treatment interruption arm, patients were
on therapy only 33% of the time. Thus, HIV viremia may
possibly explain some of the findings, particularly the increase
in non-HIV-related complications.
The main limitation to this study is the concern that the
restart level of 250 CD4 cells/mm3 may have been too low.
Both SMART and the smaller Trivican study,10 which used this
threshold, have reported increased mortality and morbidity.
Another small study, STACATTO,11 which used a CD4 thresh-
old of 350 cell/mm3, reported this strategy to be safe and
effective. Thus, it remains to be seen whether CD4-guided
intermittent therapy may be feasible with a higher threshold
for restarting therapy.
In conclusion, in the SMART trail, CD4-guided intermittent
therapy was associated with increased risk of clinical AIDS,
severe complications, and death. Currently, the DHHS expert
guidelines “cautions patients and clinicians that treatment
interruption should only be done in the setting of a clinical trial
and under close observation.”4
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